IP Library Granted Patent US 9,284,531
Granted Patent B2
US 9,284,531 · App. 13/376,610 · Granted Mar 15, 2016

Differentiation of human pluripotent stem cells into cells expressing mature hepatocyte markers by 2D and bioreactor culture

Inventors: Harald Stachelscheid (Berlin, DE); Katrin Zeilinger (Berlin, DE); Janne Jensen (Gothenburg, SE); Thomas Urbaniak (Berlin, DE)
Assignee: Takara Bio Europe AB
C12N5/067C12M25/10C12N5/0671C12N2500/25C12N2500/34C12N2501/11C12N2501/113C12N2501/115C12N2501/12C12N2501/155C12N2501/16C12N2501/23C12N2501/39C12N2501/70C12N2506/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,284,531
App. No.
13/376,610
Granted
Mar 15, 2016
Kind
B2
Abstract

The present invention relates to the use of 3D culturing systems for the derivation of hepatocyte-like cells from human pluripotent stem cells (hPS). In particular, the invention concerns the directed differentiation and maturation of human pluripotent stem cells into hepatocyte like cells in 3D hollow fiber capillary bioreactors.

Claims (19)

1. A method for differentiation of human pluripotent stem cells into cells expressing mature hepatocyte markers comprising:

i) culturing human pluripotent stem (hPS) cells in a 2D feeder-free culture system in a low serum culture medium comprising Activin A to produce cells differentiating towards definitive endoderm (DE);

ii) seeding the cells of step i) in a bioreactor;

iii) perfusing the bioreactor with one or more culture media selected from a medium comprising low serum, bFGF and Activin A; a medium comprising serum, bFGF and Activin A; or a medium comprising serum, aFGF, bFGF, BMP2 and BMP4 to induce differentiation of DE into cells expressing AFP at about day 17; and

iv) perfusing the bioreactors containing the AFP expressing cells of step ii) with a culture medium comprising bFGF, HGF, Oncostatin M, and Dexamethasone or in a culture medium comprising HGF, Oncostatin M, Dexamethasone, and DMSO, wherein resulting cells express AFP, albumin and urea; wherein the perfused cells of step (ii) differentiate into cells that express the mature hepatic markers Albumin, CYP3A4, UGT2B7, OATP-2, ADH1A, UGTIA6, CYP2C9, CYP2C19, and CYP2D6.

2. The method according to claim 1 , wherein the cells expressing mature hepatocyte markers form a 3D tissue structure.

3. The method according to claim 1 or 2 , wherein the hPS cells are human embryonic stem cells.

4. The method according to claim 1 or 2 , wherein the hPS cells are induced pluripotent stem (iPS) cells.

5. The method according to claim 1 , wherein the bioreactor is a hollow fiber capillary bioreactor.

6. The method according to claim 1 , wherein the bioreactor is provided with membrane compartments.

7. The method according to claim 6 , wherein the membrane compartments comprise two or more capillary systems and one or more hollow fiber membrane.

8. The method according to any one of claims 5 to 7 , wherein the bioreactor comprises a capillary system for perfusion of culture medium through the capillary system and a capillary system for gas exchange.

9. The method according to claim 8 , wherein perfusion of growth medium takes place through the capillary system and gas exchange takes place via a hollow fiber membrane system.

10. The method according to claim 9 , wherein the capillary system and one or more hollow fiber membranes are configured to form independent interwoven fiber capillary membrane systems integrated into a housing.

11. The method according to claim 1 , wherein the bioreactor is inoculated with inactivated fibroblast feeder cells prior to step ii).

12. The method according to claim 11 , wherein the feeder cells are human foreskin fibroblasts (hFF) or mouse embryonic feeder (MEF) cells.

13. The method according to claim 1 , wherein the bioreactor is co-inoculated with human blastocyst-derived stem (hBS) cells and inactivated fibroblast feeder cells or definitive endoderm cells and inactivated fibroblast feeder cells.

14. The method according to claim 1 , wherein the culture media comprises a cell survival factor.

15. The method according to claim 1 , wherein the culture media comprises an inhibitor of ROCK Rho kinase.

Assignments (2)
CHANGE OF NAME Recorded Jun 12, 2015
From: CELLARTIS AB
To: TAKARA BIO EUROPE AB
Reel/Frame 035903/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2012
From: STACHELSCHEID, HARALD; ZEILINGER, KATRIN; JENSEN, JANNE; URBANIAK, THOMAS
To: CELLARTIS AB
Reel/Frame 027576/0562 →
Priority Claims (1)
DK 2009 00751 · Jun 18, 2009 · national
Continuity (2)
Provisional Application 61218140 · Jun 18, 2009
Related Publication 20120115226A1 · May 10, 2012